We are live on ! Find out more
PRME icon

Prime Medicine
PRME

66 hedge funds and large institutions have $768M invested in Prime Medicine in 2022 Q4 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

42.51% more ownership

Funds ownership: 0% → 42.51% (+43%)

Holders
66
Holders Change
+66
Holders Change %
–
% of All Funds
1.06%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
66
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AI
Alphabet Inc
California
+$240M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$153M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$43M
4
RG
Redmile Group
California
+$39.9M
5
MM
MWG Management
British Virgin Islands
+$33.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$247M +$240M +13,284,688 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$157M +$153M +8,463,046 New
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$44.2M +$43M +2,378,582 New
RG
4
Redmile Group
California
$41M +$39.9M +2,209,350 New
MM
5
MWG Management
British Virgin Islands
$34.1M +$33.2M +1,835,876 New
Fidelity International
6
Fidelity International
Bermuda
$33.5M +$32.6M +1,805,558 New
AIM
7
ARK Investment Management
Florida
$30.5M +$29.6M +1,639,984 New
BlackRock
8
BlackRock
New York
$27.6M +$26.9M +1,487,846 New
BBA
9
Baker Bros. Advisors
New York
$19.1M +$18.6M +1,028,466 New
DM
10
Deerfield Management
New York
$16.4M +$16M +885,314 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$16.2M +$15.8M +872,523 New
CC
12
Casdin Capital
New York
$13.6M +$13.3M +734,350 New
CAM
13
Cormorant Asset Management
Massachusetts
$13.6M +$13.3M +734,350 New
EC
14
EcoR1 Capital
California
$11.1M +$10.8M +600,000 New
MCM
15
Moore Capital Management
New York
$9.29M +$9.03M +500,000 New
Sumitomo Mitsui Trust Group
16
Sumitomo Mitsui Trust Group
Japan
$9.07M +$8.82M +488,226 New
NAMA
17
Nikko Asset Management Americas
New York
$9.04M +$8.82M +488,226 New
SB
18
Samsara BioCapital
California
$8.74M +$8.5M +470,304 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$4.35M +$4.23M +234,295 New
Ensign Peak Advisors
20
Ensign Peak Advisors
Utah
$2.79M +$2.71M +150,000 New
OMC
21
OUP Management Company
Pennsylvania
$2.25M +$2.19M +121,255 New
State Street
22
State Street
Massachusetts
$2.13M +$2.07M +114,846 New
CCM
23
CAAS Capital Management
New York
$1.66M +$1.61M +89,331 New
Northern Trust
24
Northern Trust
Illinois
$1.55M +$1.51M +83,546 New
Charles Schwab
25
Charles Schwab
California
$1.32M +$1.29M +71,184 New
1
2 3

PRME Hedge Fund Activity: Q4 2022 in Review

66 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q4 2022, worth a combined $768M.

Buyers outnumbered sellers: 66 funds opened new PRME positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Alphabet Inc, opening a new position worth an estimated $240M.

  • 66 institutional investors held Prime Medicine (PRME) as of Q4 2022, up from 0 in Q3 2022.
  • Funds reported $768M of Prime Medicine stock for Q4 2022.
  • 66 funds opened new Prime Medicine positions in Q4 2022 and 0 closed out, a net change of +66 holders.
  • The largest Prime Medicine buyer in Q4 2022 was Alphabet Inc, an estimated $240M added.

Based on aggregated 13F filings for Q4 2022.